Literature DB >> 32918948

Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.

Mingzhen Zhang1, Hyunbum Jang1, Ruth Nussinov2.   

Abstract

PI3K lipid kinases signal through the PI3K/Akt pathway, regulating cell growth and proliferation. While the structural features that distinguish between the active and inactive states of protein kinases are well established, that has not been the case for lipid kinases, and neither was the structural mechanism controlling the switch between the two states. Class I PI3Ks are obligate heterodimers with catalytic and regulatory subunits. Here, we analyze PI3K crystal structures. Structures with the nSH2 (inactive state) are featured by collapsed activation loop (a-loop) and an IN kinase domain helix 11 (kα11). In the active state, the a-loop is extended and kα11 in the OUT conformation. Our analysis suggests that the nSH2 domain in the regulatory subunit regulates activation, catalysis and autoinhibition through the a-loop. Inhibition, activation and catalytic scenarios are shared by class IA PI3Ks; the activation is mimicked by oncogenic mutations and the inhibition offers an allosteric inhibitor strategy.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  PI3K mutations; PI3Kα; Ras; catalytic and regulatory subunits; nSH2

Mesh:

Substances:

Year:  2020        PMID: 32918948      PMCID: PMC8916166          DOI: 10.1016/j.jmb.2020.09.002

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  41 in total

1.  Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.

Authors:  L Pirola; M J Zvelebil; G Bulgarelli-Leva; E Van Obberghen; M D Waterfield; M P Wymann
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

2.  Rare cancer-specific mutations in PIK3CA show gain of function.

Authors:  Marco Gymnopoulos; Marc-André Elsliger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-21       Impact factor: 11.205

3.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

4.  Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Authors:  Pedram Razavi; Jared L Johnson; Hong Shao; Neil Vasan; Hardik Shah; Alesia Antoine; Erik Ladewig; Alexander Gorelick; Ting-Yu Lin; Eneda Toska; Guotai Xu; Abiha Kazmi; Matthew T Chang; Barry S Taylor; Maura N Dickler; Komal Jhaveri; Sarat Chandarlapaty; Raul Rabadan; Ed Reznik; Melissa L Smith; Robert Sebra; Frauke Schimmoller; Timothy R Wilson; Lori S Friedman; Lewis C Cantley; Maurizio Scaltriti; José Baselga
Journal:  Science       Date:  2019-11-08       Impact factor: 47.728

5.  Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.

Authors:  Sweta Maheshwari; Michelle S Miller; Robert O'Meally; Robert N Cole; L Mario Amzel; Sandra B Gabelli
Journal:  J Biol Chem       Date:  2017-07-04       Impact factor: 5.157

6.  Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.

Authors:  Xuxiao Zhang; Oscar Vadas; Olga Perisic; Karen E Anderson; Jonathan Clark; Phillip T Hawkins; Len R Stephens; Roger L Williams
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

7.  Clustal Omega for making accurate alignments of many protein sequences.

Authors:  Fabian Sievers; Desmond G Higgins
Journal:  Protein Sci       Date:  2017-10-30       Impact factor: 6.725

8.  Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.

Authors:  Paraskevi Gkeka; Thomas Evangelidis; Maria Pavlaki; Vasiliki Lazani; Savvas Christoforidis; Bogos Agianian; Zoe Cournia
Journal:  PLoS Comput Biol       Date:  2014-10-23       Impact factor: 4.475

Review 9.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

10.  The mechanism of PI3Kα activation at the atomic level.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Chem Sci       Date:  2019-02-20       Impact factor: 9.825

View more
  7 in total

1.  Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Nan Jin; Bhumsuk Keam; Janice Cho; Michelle J Lee; Hye Ryun Kim; Hayarpi Torosyan; Natalia Jura; Patrick Ks Ng; Gordon B Mills; Hua Li; Yan Zeng; Zohar Barbash; Gabi Tarcic; Hyunseok Kang; Julie E Bauman; Mi-Ok Kim; Nathan K VanLandingham; Danielle L Swaney; Nevan J Krogan; Daniel E Johnson; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

2.  Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma.

Authors:  Suparna Ghosh; Seung Joo Cho
Journal:  Biomedicines       Date:  2022-03-30

Review 3.  PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Cancer Res       Date:  2020-10-12       Impact factor: 13.312

Review 4.  Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.

Authors:  Ruth Nussinov; Mingzhen Zhang; Chung-Jung Tsai; Hyunbum Jang
Journal:  Mol Cancer Res       Date:  2020-12-07       Impact factor: 6.333

5.  Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.

Authors:  Jonathan R Hart; Xiao Liu; Chen Pan; Anyi Liang; Lynn Ueno; Yingna Xu; Alexandra Quezada; Xinyu Zou; Su Yang; Qingtong Zhou; Steve Schoonooghe; Gholamreza Hassanzadeh-Ghassabeh; Tian Xia; Wenqing Shui; Dehua Yang; Peter K Vogt; Ming-Wei Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-12       Impact factor: 12.779

6.  Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).

Authors:  Teresa Liliana Wargasetia; Hana Ratnawati; Nashi Widodo; Muhammad Hermawan Widyananda
Journal:  Cancer Inform       Date:  2021-07-13

Review 7.  Mechanism of activation and the rewired network: New drug design concepts.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Chung-Jung Tsai; Bengi Ruken Yavuz; Nurcan Tuncbag; Hyunbum Jang
Journal:  Med Res Rev       Date:  2021-10-25       Impact factor: 12.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.